Jcell is under clinical development by JCyte and currently in Phase II for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase II drugs for Retinitis Pigmentosa (Retinitis) have a 58% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Jcell’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Jcell overview

Stem cell therapy (jcell) is under development for the treatment of Retinitis pigmentosa (RP) and other inherited retinal and blinding diseases. Retinal progenitor cells are developed by human retinal progenital cell (hRPC) technology. It is administered by intravitreal route.

It was also under development for the treatment of age-related macular degeneration (AMD), cone rod dystrophy and stargardt's disease.

JCyte overview

jCyte is a biotechnology company that discovers and develops regenerative cell-therapies for retinal degenerative diseases. It is investigating jCell, an intravitreal injection for the treatment of retinitis pigmentosa (RP) and other dystrophies. The company is also evaluating drug development programs for retinitis pigmentosa, cone rod dystrophy, Stargardt’s disease, and dry AMD; glaucoma and optic neuropathies; vascular and metabolic degenerative disorders such as diabetic retinopathy. It works in partnership with Santen Pharmaceutical Co Ltd, California Institute for Regenerative Medicine, Discovery Eye Foundation, and University of California, Irvine. jCyte is headquartered in Newport Beach, California, the US.

For a complete picture of Jcell’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.